Impact of IPT With Sulfadoxin Pyrimetamin on Pregnant Women and Their Babies Outcomes in Peri-urban Areas of Bobo-Dioulasso(Burkina Faso)
This study has been completed.
Information provided by (Responsible Party):
Dr Mamoudou Cisse, Centre Muraz
First received: December 6, 2010
Last updated: June 15, 2012
Last verified: June 2012
The purpose of this is to determine the impact of intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) on the morbidities associated with malaria in pregnant women and newborns in rural peri-urban areas of Bobo-Dioulasso, 5 years after its implemented.
||Time Perspective: Cross-Sectional
||Impact of Intermittent Preventive Treatment (IPT) With Sulfadoxine-pyrimethamine (SP) on the Morbidities Associated With Malaria in Pregnant Women and Newborns in Peri-urban Areas of Bobo-Dioulasso, 5 Years After Its Adoption by the National Program for Fight Against Malaria in Burkina Faso.
Primary Outcome Measures:
Biospecimen Retention: Samples With DNA
Secondary Outcome Measures:
- Maternal anemia, congenital malaria,low birth weight, prematurity. [ Time Frame: Maternal anemia: at antenatal clinics and at delivery. Congenital malaria: at delivery. Low birth weight: at delivery. Prematurity: at delivery. ]
The investigators will check pregnant women haemoglobin level.A level< 11g/dl will be considered as anemia.
Congenital malaria will be assessed through cord blood smear. Birth weight <2500g will be considered as low birth weight. Prematurity designs any birth before 37 gestation weeks.
The investigators make thick and thin blood smear and collect a few drops of blood on the 3MM paper Whatmann Schleicher-Schuell.
| Study Start Date:
| Study Completion Date:
Malaria in pregnant women is a crucial issue in Burkina Faso. Faced with this problem, a strategy based on the use of treated nets and intermittent preventive treatment (IPT) based on sulfadoxine-pyrimethamine (SP) was adopted in 2005. Five years after its implementation, the investigators will check whether this strategy is still effective in the preventing maternal and congenital malaria on the one hand and maternal anemia, low birth weight and prematurity on the other hand.
|Ages Eligible for Study:
||Child, Adult, Senior
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Our study population is constitued by pregnant women coming for antenatal care or delivery in two peripheral heath facilities of Bobo-Dioulasso(Lafiabougou and Secteur 24).
- Residing in the health area of Lafiabougou or secteur 24
- Having agreed to give free and informed consent
- Bleeding from during the pregnancy
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01255605
|Institut Supérieur des Sciences de la Santé/Université Polytechnique de Bobo-Dioulasso
|Bobo-Dioulasso, Houet, Burkina Faso, 1091 |
Université Polytechnique de Bobo-Dioulasso
||Mamoudou Cisse, MD
||Centre MURAZ Research Institute
||Dr Mamoudou Cisse, Medical doctor, Centre Muraz
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 6, 2010
||June 15, 2012
Keywords provided by Dr Mamoudou Cisse, Centre Muraz:
Intermittent preventive treatment with sulfadoxin-pyrimethamine
in Bobo-Dioulasso peri-urban areas, 5 years after its implementation
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on June 28, 2017
Folic Acid Antagonists
Molecular Mechanisms of Pharmacological Action